INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).

The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.

Study Overview

• Status: Completed
• Conditions: Myelofibrosis
• Intervention / Treatment: Drug: INC424

• Study Type: Interventional
• Enrollment (Actual): 2233
• Phase: Phase 3

Contacts and Locations

Study Locations

• Algeria
  • Alger, Algeria
    • Novartis Investigative Site
• Argentina
  • Buenos Aires, Argentina, C1114AAN
    • Novartis Investigative Site
  • Cordoba, Argentina, X5016KEH
    • Novartis Investigative Site
  • Corrientes, Argentina, W3410AVV
    • Novartis Investigative Site
  • Buenos Aires
    • Caba, Buenos Aires, Argentina, C1221ADC
      • Novartis Investigative Site
    • Caba, Buenos Aires, Argentina, 1209
      • Novartis Investigative Site
  • Entre Rios
    • Paraná, Entre Rios, Argentina, E3100BBJ
      • Novartis Investigative Site
• Austria
  • Graz, Austria, A-8036
    • Novartis Investigative Site
  • Linz, Austria, A-4010
    • Novartis Investigative Site
  • Linz, Austria, 4010
    • Novartis Investigative Site
  • Salzburg, Austria, 5020
    • Novartis Investigative Site
  • Wien, Austria, A-1090
    • Novartis Investigative Site
  • Wien, Austria, 1140
    • Novartis Investigative Site
  • Tyrol
    • Innsbruck, Tyrol, Austria, 6020
      • Novartis Investigative Site
• Belgium
  • Antwerpen, Belgium, 2060
    • Novartis Investigative Site
  • Brugge, Belgium, 8000
    • Novartis Investigative Site
  • Brussel, Belgium, 1090
    • Novartis Investigative Site
  • Bruxelles, Belgium, 1070
    • Novartis Investigative Site
  • Charleroi, Belgium, 6000
    • Novartis Investigative Site
  • Edegem, Belgium, 2650
    • Novartis Investigative Site
  • Gent, Belgium, 9000
    • Novartis Investigative Site
  • Hasselt, Belgium, 3500
    • Novartis Investigative Site
  • Kortrijk, Belgium, 8500
    • Novartis Investigative Site
  • Leuven, Belgium, 3000
    • Novartis Investigative Site
  • Liege, Belgium, 4000
    • Novartis Investigative Site
  • Roeselare, Belgium, 8800
    • Novartis Investigative Site
  • Wilrijk, Belgium, 2610
    • Novartis Investigative Site
  • Yvoir, Belgium, 5530
    • Novartis Investigative Site
  • Luxembourg
    • Arlon, Luxembourg, Belgium, 1210
      • Novartis Investigative Site
• Brazil
  • GO
    • Goiania, GO, Brazil, 74605-050
      • Novartis Investigative Site
  • MG
    • Belo Horizonte, MG, Brazil, 30130-100
      • Novartis Investigative Site
  • PR
    • Curitiba, PR, Brazil, 80060-900
      • Novartis Investigative Site
  • RJ
    • Rio de Janeiro, RJ, Brazil, 20.211-030
      • Novartis Investigative Site
  • RS
    • Porto Alegre, RS, Brazil, 90035-003
      • Novartis Investigative Site
  • SP
    • Campinas, SP, Brazil, 13083-970
      • Novartis Investigative Site
    • Ribeirao Preto, SP, Brazil, 14048-900
      • Novartis Investigative Site
    • São Paulo, SP, Brazil, 01224-000
      • Novartis Investigative Site
    • São Paulo, SP, Brazil, 05651-901
      • Novartis Investigative Site
    • São Paulo, SP, Brazil, 08270-070
      • Novartis Investigative Site
• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Novartis Investigative Site
  • British Columbia
    • Vancouver, British Columbia, Canada, V6Z1Y6
      • Novartis Investigative Site
  • New Brunswick
    • Moncton, New Brunswick, Canada, E1C 6Z8
      • Novartis Investigative Site
  • Newfoundland and Labrador
    • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
      • Novartis Investigative Site
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 1V7
      • Novartis Investigative Site
  • Ontario
    • Hamilton, Ontario, Canada, L8V 5C2
      • Novartis Investigative Site
    • Ottawa, Ontario, Canada, K1H 8L6
      • Novartis Investigative Site
    • Toronto, Ontario, Canada, M5G 2M9
      • Novartis Investigative Site
    • Windsor, Ontario, Canada, N8W 2X3
      • Novartis Investigative Site
  • Quebec
    • Montreal, Quebec, Canada, H2W 1S6
      • Novartis Investigative Site
    • Québec, Quebec, Canada, G1J 1Z4
      • Novartis Investigative Site
  • Saskatchewan
    • Saskatoon, Saskatchewan, Canada, S7N 4H4
      • Novartis Investigative Site
• Colombia
  • Medellín, Colombia
    • Novartis Investigative Site
  • Cundinamarca
    • Bogota, Cundinamarca, Colombia, 111411
      • Novartis Investigative Site
• Czechia
  • Olomouc, Czechia, 775 20
    • Novartis Investigative Site
  • Czech Republic
    • Brno, Czech Republic, Czechia, 639 00
      • Novartis Investigative Site
    • Hradec Kralove, Czech Republic, Czechia, 500 05
      • Novartis Investigative Site
    • Praha 2, Czech Republic, Czechia, 128 20
      • Novartis Investigative Site
• Germany
  • Aachen, Germany, 52074
    • Novartis Investigative Site
  • Aschaffenburg, Germany, 63739
    • Novartis Investigative Site
  • Bamberg, Germany, 96049
    • Novartis Investigative Site
  • Berlin, Germany, 13353
    • Novartis Investigative Site
  • Berlin, Germany, 14195
    • Novartis Investigative Site
  • Bochum, Germany, 44787
    • Novartis Investigative Site
  • Bonn, Germany, 53119
    • Novartis Investigative Site
  • Bonn, Germany, 53113
    • Novartis Investigative Site
  • Bottrop, Germany, 46236
    • Novartis Investigative Site
  • Bremen, Germany, 28177
    • Novartis Investigative Site
  • Chemnitz, Germany, 09113
    • Novartis Investigative Site
  • Darmstadt, Germany, 64283
    • Novartis Investigative Site
  • Dortmund, Germany, 44263
    • Novartis Investigative Site
  • Dresden, Germany, 01307
    • Novartis Investigative Site
  • Duisburg, Germany, 47166
    • Novartis Investigative Site
  • Düsseldorf, Germany, 40225
    • Novartis Investigative Site
  • Erlangen, Germany, 91054
    • Novartis Investigative Site
  • Essen, Germany, 45147
    • Novartis Investigative Site
  • Frankfurt, Germany, 60590
    • Novartis Investigative Site
  • Frankfurt, Germany, 60389
    • Novartis Investigative Site
  • Frankfurt, Oder, Germany, 15236
    • Novartis Investigative Site
  • Freiburg, Germany, 79106
    • Novartis Investigative Site
  • Friedrichshafen, Germany, 88045
    • Novartis Investigative Site
  • Goslar, Germany, 38642
    • Novartis Investigative Site
  • Greifswald, Germany, 17475
    • Novartis Investigative Site
  • Göttingen, Germany, D-37075
    • Novartis Investigative Site
  • Halle, Germany, 06110
    • Novartis Investigative Site
  • Hamburg, Germany, 20246
    • Novartis Investigative Site
  • Hamburg, Germany, 20099
    • Novartis Investigative Site
  • Hamm, Germany, 59063
    • Novartis Investigative Site
  • Hannover, Germany, 30625
    • Novartis Investigative Site
  • Hildesheim, Germany, 31135
    • Novartis Investigative Site
  • Ingolstadt, Germany, 85049
    • Novartis Investigative Site
  • Jena, Germany, 07740
    • Novartis Investigative Site
  • Kiel, Germany, D-24116
    • Novartis Investigative Site
  • Koeln, Germany, 50671
    • Novartis Investigative Site
  • Köln, Germany, 50937
    • Novartis Investigative Site
  • Leer, Germany, 26789
    • Novartis Investigative Site
  • Leipzig, Germany, 04103
    • Novartis Investigative Site
  • Magdeburg, Germany, 39120
    • Novartis Investigative Site
  • Mainz, Germany, 55131
    • Novartis Investigative Site
  • Marburg, Germany, 35037
    • Novartis Investigative Site
  • Marburg, Germany, 35039
    • Novartis Investigative Site
  • Minden, Germany, 32429
    • Novartis Investigative Site
  • Moers, Germany, 47441
    • Novartis Investigative Site
  • Muenchen, Germany, 80331
    • Novartis Investigative Site
  • Muenchen, Germany, 81241
    • Novartis Investigative Site
  • München, Germany, 81675
    • Novartis Investigative Site
  • Nuernberg, Germany, 90403
    • Novartis Investigative Site
  • Oldenburg, Germany, 26133
    • Novartis Investigative Site
  • Rostock, Germany, 18057
    • Novartis Investigative Site
  • Stuttgart, Germany, 70376
    • Novartis Investigative Site
  • Ulm, Germany, 89081
    • Novartis Investigative Site
  • Wuerzburg, Germany, 97080
    • Novartis Investigative Site
  • Baden-Württemberg
    • Mannheim, Baden-Württemberg, Germany, 68305
      • Novartis Investigative Site
• Greece
  • Athens, Greece, GR 11527
    • Novartis Investigative Site
  • Patras, Greece, 265 00
    • Novartis Investigative Site
  • GR
    • Athens, GR, Greece, 115 27
      • Novartis Investigative Site
    • Athens, GR, Greece, GR-106 76
      • Novartis Investigative Site
• Hungary
  • Budapest, Hungary, H-1097
    • Novartis Investigative Site
  • Debrecen, Hungary, H-4032
    • Novartis Investigative Site
  • Kaposvár, Hungary, 7400
    • Novartis Investigative Site
  • Szeged, Hungary, H-6720
    • Novartis Investigative Site
  • Szombathely, Hungary, 9700
    • Novartis Investigative Site
• Ireland
  • Cork
    • Cork City, Cork, Ireland
      • Novartis Investigative Site
• Israel
  • Afula, Israel, 1834111
    • Novartis Investigative Site
  • Haifa, Israel, 3339419
    • Novartis Investigative Site
  • Jerusalem, Israel, 9112001
    • Novartis Investigative Site
  • Petach Tikva, Israel, 49100
    • Novartis Investigative Site
  • Ramat Gan, Israel, 5266202
    • Novartis Investigative Site
  • Tel-Aviv, Israel, 6423906
    • Novartis Investigative Site
• Italy
  • Napoli, Italy, 80131
    • Novartis Investigative Site
  • Napoli, Italy, 80132
    • Novartis Investigative Site
  • Napoli, Italy, 80136
    • Novartis Investigative Site
  • Novara, Italy, 28100
    • Novartis Investigative Site
  • Pavia, Italy, 27100
    • Novartis Investigative Site
  • Perugia, Italy, 06129
    • Novartis Investigative Site
  • AL
    • Alessandria, AL, Italy, 15100
      • Novartis Investigative Site
  • AN
    • Ancona, AN, Italy, 60126
      • Novartis Investigative Site
  • AV
    • Avellino, AV, Italy, 83100
      • Novartis Investigative Site
  • BA
    • Bari, BA, Italy, 70124
      • Novartis Investigative Site
  • BG
    • Bergamo, BG, Italy, 24128
      • Novartis Investigative Site
  • BO
    • Bologna, BO, Italy, 40138
      • Novartis Investigative Site
  • BS
    • Brescia, BS, Italy, 25123
      • Novartis Investigative Site
  • CA
    • Cagliari, CA, Italy, 09100
      • Novartis Investigative Site
    • Cagliari, CA, Italy, 09126
      • Novartis Investigative Site
  • CT
    • Catania, CT, Italy, 95124
      • Novartis Investigative Site
    • Catania, CT, Italy, 95100
      • Novartis Investigative Site
  • CZ
    • Catanzaro, CZ, Italy, 88100
      • Novartis Investigative Site
  • FE
    • Cona, FE, Italy, 44100
      • Novartis Investigative Site
  • FG
    • San Giovanni Rotondo, FG, Italy, 71013
      • Novartis Investigative Site
  • FI
    • Firenze, FI, Italy, 50134
      • Novartis Investigative Site
  • GE
    • Genova, GE, Italy, 16132
      • Novartis Investigative Site
  • LE
    • Lecce, LE, Italy, 73100
      • Novartis Investigative Site
  • MB
    • Monza, MB, Italy, 20900
      • Novartis Investigative Site
  • MI
    • Milano, MI, Italy, 20162
      • Novartis Investigative Site
    • Milano, MI, Italy, 20133
      • Novartis Investigative Site
    • Milano, MI, Italy, 20122
      • Novartis Investigative Site
  • MO
    • Modena, MO, Italy, 41100
      • Novartis Investigative Site
  • PA
    • Palermo, PA, Italy, 90146
      • Novartis Investigative Site
  • PD
    • Padova, PD, Italy, 35128
      • Novartis Investigative Site
  • PE
    • Pescara, PE, Italy, 65124
      • Novartis Investigative Site
  • PI
    • Pisa, PI, Italy, 56126
      • Novartis Investigative Site
  • PU
    • Pesaro, PU, Italy, 61100
      • Novartis Investigative Site
  • PV
    • Pavia, PV, Italy, 27100
      • Novartis Investigative Site
  • PZ
    • Rionero in Vulture, PZ, Italy, 85028
      • Novartis Investigative Site
  • RA
    • Ravenna, RA, Italy, 48100
      • Novartis Investigative Site
  • RC
    • Reggio Calabria, RC, Italy, 89124
      • Novartis Investigative Site
  • RE
    • Reggio Emilia, RE, Italy, 42123
      • Novartis Investigative Site
  • RM
    • Roma, RM, Italy, 00168
      • Novartis Investigative Site
    • Roma, RM, Italy, 00152
      • Novartis Investigative Site
    • Roma, RM, Italy, 00128
      • Novartis Investigative Site
    • Roma, RM, Italy, 00144
      • Novartis Investigative Site
    • Roma, RM, Italy, 00161
      • Novartis Investigative Site
    • Roma, RM, Italy, 00133
      • Novartis Investigative Site
    • Roma, RM, Italy, 00185
      • Novartis Investigative Site
  • SA
    • Pagani, SA, Italy, 84016
      • Novartis Investigative Site
  • SI
    • Siena, SI, Italy, 53100
      • Novartis Investigative Site
  • TA
    • Taranto, TA, Italy, 74100
      • Novartis Investigative Site
  • TO
    • Orbassano, TO, Italy, 10043
      • Novartis Investigative Site
    • Torino, TO, Italy, 10126
      • Novartis Investigative Site
  • TR
    • Terni, TR, Italy, 05100
      • Novartis Investigative Site
  • TV
    • Treviso, TV, Italy, 31100
      • Novartis Investigative Site
  • UD
    • Udine, UD, Italy, 33100
      • Novartis Investigative Site
  • VA
    • Varese, VA, Italy, 21100
      • Novartis Investigative Site
  • VE
    • Venezia, VE, Italy, 30174
      • Novartis Investigative Site
  • VI
    • Vicenza, VI, Italy, 36100
      • Novartis Investigative Site
  • VR
    • Verona, VR, Italy, 37126
      • Novartis Investigative Site
  • VT
    • Ronciglione, VT, Italy, 01100
      • Novartis Investigative Site
• Mexico
  • Puebla, Mexico, 72000
    • Novartis Investigative Site
  • Distrito Federal
    • Mexico, Distrito Federal, Mexico, 06726
      • Novartis Investigative Site
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44280
      • Novartis Investigative Site
  • Nuevo León
    • Monterrey, Nuevo León, Mexico, 64020
      • Novartis Investigative Site
  • Sonora
    • Hermosillo, Sonora, Mexico, 83000
      • Novartis Investigative Site
• Morocco
  • Marrakech, Morocco
    • Novartis Investigative Site
• Poland
  • Gdansk, Poland, 80-958
    • Novartis Investigative Site
  • Katowice, Poland, 40-027
    • Novartis Investigative Site
  • Krakow, Poland, 31-503
    • Novartis Investigative Site
  • Opole, Poland, 45-372
    • Novartis Investigative Site
  • Torun, Poland, 87-100
    • Novartis Investigative Site
  • Warszawa, Poland, 02-776
    • Novartis Investigative Site
• Portugal
  • Coimbra, Portugal, 3000-075
    • Novartis Investigative Site
  • Faro, Portugal, 8000-386
    • Novartis Investigative Site
  • Lisboa, Portugal, 1749-035
    • Novartis Investigative Site
  • Porto, Portugal, 4099-001
    • Novartis Investigative Site
  • Vila Real, Portugal, 5000 - 508
    • Novartis Investigative Site
• Russian Federation
  • Irkutsk, Russian Federation, 664079
    • Novartis Investigative Site
  • Moscow, Russian Federation, 125167
    • Novartis Investigative Site
  • Nizhnii Novgorod, Russian Federation, 603126
    • Novartis Investigative Site
  • Novosibirsk, Russian Federation, 630051
    • Novartis Investigative Site
  • Rostov-on-Don, Russian Federation, 344022
    • Novartis Investigative Site
  • St Petersburg, Russian Federation, 191024
    • Novartis Investigative Site
  • St Petersburg, Russian Federation, 197341
    • Novartis Investigative Site
• Saudi Arabia
  • Jeddah, Saudi Arabia, 21423
    • Novartis Investigative Site
  • Riyadh, Saudi Arabia, 11426
    • Novartis Investigative Site
• Slovakia
  • Bratislava, Slovakia, 85107
    • Novartis Investigative Site
• South Africa
  • Johannesburg, South Africa, 2196
    • Novartis Investigative Site
  • Pretoria, South Africa, 0027
    • Novartis Investigative Site
  • Pretoria, South Africa, 0001
    • Novartis Investigative Site
  • Gauteng
    • Soweto, Gauteng, South Africa, 2013
      • Novartis Investigative Site
  • Western Province
    • Cape Town, Western Province, South Africa, 7801
      • Novartis Investigative Site
• Spain
  • Barcelona, Spain, 08041
    • Novartis Investigative Site
  • Las Palmas de Gran Canaria, Spain, 35016
    • Novartis Investigative Site
  • Madrid, Spain, 28041
    • Novartis Investigative Site
  • Madrid, Spain, 28034
    • Novartis Investigative Site
  • Madrid, Spain, 28046
    • Novartis Investigative Site
  • Madrid, Spain, 28006
    • Novartis Investigative Site
  • Madrid, Spain, 28040
    • Novartis Investigative Site
  • Zaragoza, Spain, 50009
    • Novartis Investigative Site
  • Zaragoza, Spain, 50015
    • Novartis Investigative Site
  • A Coruna
    • Ferrol, A Coruna, Spain, 15405
      • Novartis Investigative Site
  • Andalucia
    • Granada, Andalucia, Spain, 18014
      • Novartis Investigative Site
    • Malaga, Andalucia, Spain, 29010
      • Novartis Investigative Site
    • Sevilla, Andalucia, Spain, 41013
      • Novartis Investigative Site
    • Sevilla, Andalucia, Spain, 41009
      • Novartis Investigative Site
  • Andalucía
    • Cadiz, Andalucía, Spain, 11009
      • Novartis Investigative Site
    • Jaen, Andalucía, Spain, 23007
      • Novartis Investigative Site
  • Asturias
    • Oviedo, Asturias, Spain, 33006
      • Novartis Investigative Site
  • Barcelona
    • Sabadell, Barcelona, Spain, 08208
      • Novartis Investigative Site
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Novartis Investigative Site
  • Castilla La Mancha
    • Toledo, Castilla La Mancha, Spain, 45071
      • Novartis Investigative Site
  • Castilla Y Leon
    • Burgos, Castilla Y Leon, Spain, 09005
      • Novartis Investigative Site
    • Salamanca, Castilla Y Leon, Spain, 37007
      • Novartis Investigative Site
    • Valladolid, Castilla Y Leon, Spain, 47012
      • Novartis Investigative Site
  • Catalunya
    • Badalona, Catalunya, Spain, 08916
      • Novartis Investigative Site
    • Barcelona, Catalunya, Spain, 08035
      • Novartis Investigative Site
    • Barcelona, Catalunya, Spain, 08036
      • Novartis Investigative Site
    • Barcelona, Catalunya, Spain, 08003
      • Novartis Investigative Site
    • Girona, Catalunya, Spain, 17007
      • Novartis Investigative Site
    • Hospitalet de LLobregat, Catalunya, Spain, 08907
      • Novartis Investigative Site
    • Tarragona, Catalunya, Spain, 43005
      • Novartis Investigative Site
  • Comunidad Valenciana
    • Alicante, Comunidad Valenciana, Spain, 03010
      • Novartis Investigative Site
    • Valencia, Comunidad Valenciana, Spain, 46026
      • Novartis Investigative Site
    • Valencia, Comunidad Valenciana, Spain, 46010
      • Novartis Investigative Site
  • Galicia
    • Santiago de Compostela, Galicia, Spain, 15706
      • Novartis Investigative Site
  • Islas Baleares
    • Palma De Mallorca, Islas Baleares, Spain, 07120
      • Novartis Investigative Site
  • Las Palmas De G.C
    • Las Palmas de Gran Canaria, Las Palmas De G.C, Spain, 35010
      • Novartis Investigative Site
  • Madrid
    • Alcala de Henares, Madrid, Spain, 28805
      • Novartis Investigative Site
    • Majadahonda, Madrid, Spain, 28222
      • Novartis Investigative Site
    • Pozuelo de Alarcón, Madrid, Spain, 28223
      • Novartis Investigative Site
    • San Sebastian de los Reyes, Madrid, Spain, 28702
      • Novartis Investigative Site
  • Murcia
    • El Palmar, Murcia, Spain, 30120
      • Novartis Investigative Site
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Novartis Investigative Site
  • Pais Vasco
    • Bilbao, Pais Vasco, Spain, 48013
      • Novartis Investigative Site
    • San Sebastian, Pais Vasco, Spain, 20080
      • Novartis Investigative Site
  • Rioja
    • Logrono, Rioja, Spain, 26006
      • Novartis Investigative Site
  • Santa Cruz De Tenerife
    • La Laguna, Santa Cruz De Tenerife, Spain, 38320
      • Novartis Investigative Site
  • Vizcaya
    • Baracaldo, Vizcaya, Spain, 48903
      • Novartis Investigative Site
• Thailand
  • Bangkok, Thailand, 10330
    • Novartis Investigative Site
  • Bangkok, Thailand, 10700
    • Novartis Investigative Site
  • Bangkok, Thailand, 10400
    • Novartis Investigative Site
  • Chiang Mai, Thailand, 50200
    • Novartis Investigative Site
• Tunisia
  • Sousse, Tunisia, 4000
    • Novartis Investigative Site
  • Tunis, Tunisia
    • Novartis Investigative Site
  • Tunis, Tunisia, 1008
    • Novartis Investigative Site
  • Tunisie
    • Sfax, Tunisie, Tunisia, 3029
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Inclusion Criteria:

1. Patients must not be eligible for another ongoing INC424 clinical trial.
2. Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised International Standard Criteria, irrespective of JAK2 mutation status..

3. Patients with PMF requiring therapy must be classified as high risk (3 prognostic factors) OR intermediate risk level 2 (2 prognostic factors, no more), OR intermediate risk level 1 (1 prognostic factor, no more) with an enlarged spleen (assessment to occur at the Screening Visit).

   The prognostic factors, defined by the International Working Group are:

   • Age > 65 years;
   • Presence of constitutional symptoms (weight loss, fever, night sweats);
   • Marked anemia (Hgb < 10g/dL)*;
   • Leukocytosis (history of white blood cell (WBC) > 25 x109/L);
   • Circulating blasts > 1%. * A hemoglobin value < 10 g/dL must be demonstrated during the Screening Visit for patients who are not transfusion dependent. Patients receiving regular transfusions of packed red blood cells will be considered to have hemoglobin < 10 g/dL for the purpose of evaluation of risk factors.
4. Patients with Intermediate-1 disease and splenomegaly must have a palpable spleen measuring 5 cm or greater from the costal margin to the point of greatest splenic protrusion.
5. Patients must have a peripheral blood blast count of < 10%.
6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
7. Fedratinib pretreated patients with documented complete physical examination including full neurologic examination and cardiology assessment, thiamine level testing, and MRI of the brain if indicated based on signs or symptoms. Patients pretreated with fedratinib should have completed or be receiving thiamine supplementation according to the investigator's instructions.

Main Exclusion Criteria:

1. Patients eligible for hematopoietic stem cell transplantation (suitable candidate and a suitable donor is available).
2. Patients with history of malignancy in past 3 years except for treated, early-stage squamous or basal cell carcinoma in situ.
3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral INC424 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
4. Patients with cardiac disease which in the Investigator's opinion may jeopardize the safety of the patient or the compliance with the protocol.
5. Patients with currently uncontrolled or unstable angina, rapid or paroxysmal atrial fibrillation or recent (approximately 6 months) myocardial infarction or acute coronary syndrome.
6. Patients with clinically significant bacterial, fungal, parasitic or viral infection which require therapy. Patients with acute bacterial infections requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
7. Patients with known active hepatitis A, B, C or who are HIV-positive.

8. Patients with inadequate bone marrow reserve at the Baseline visit as demonstrated by:

   • Absolute neutrophil count (ANC) ≤ 1000/µL.
   • Platelet count < 50,000/µL without the assistance of growth factors, thrombopoietic factors or platelet transfusions.
9. Patients with any history of platelet counts < 50,000/µL or ANC < 500/µL except during treatment for a myeloproliferative disorder or treatment with cytotoxic therapy for any other reason.

10. In the case of ruxolitinib pretreated patients, ruxolitinib primary resistant patients defined as:

    • No spleen reduction within the first 12 weeks after front line therapy with ruxolitinib.

    AND

    • No reduction in symptoms within the first 12 weeks after first-line treatment with ruxolitinib.

11. In the case of ruxolitinib pretreated patients, patients discontinuing ruxolitinib due to a Grade 4 Adverse event (AE) related or suspected to be related to ruxolitinib.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: INC424; 5 - 25 mg twice a day (BID)	Drug: INC424; All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.; Other Names: Ruxolitinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years	An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.	Baseline up to approximately 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With at Least 50% Reduction in Spleen Length	Spleen length was assessed by manual palpation. Assessment of spleen response was repeated until early discontinuation of the study drug and also at study completion (28 days post end of treatment visit).	Baseline up to approximately 5 years
Number of Participants With Best Overall Response (BOR) up to 5 Years According to Spleen Length	Overall response is analyzed using the spleen response, as assessed by the investigator and also by deriving the response using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. Participants with spleen length at baseline between 5 and 10 cm were reported as Responders if reporting non palpable spleen; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 100% from baseline in spleen length. Participants with spleen length at baseline more than 10 cm were reported as Responders with spleen reduction of 50% from baseline; Stable disease does not meet criteria for response or disease progression and Progressive disease with an increase of 50% from baseline in spleen length.	Baseline up to approximately 5 years
Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to Worst Post-baseline ECOG Status up to 5 Years	ECOG Performance Score has 5 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. 5 = Death.	Baseline up to approximately 5 years
Change in Functional Assessment of Cancer Therapy (FACT-TOI, FACT-G) and FACT-Lymphoma (FACT-Lym) Total Scores Measured at Baseline and Week 48	The FACT-Lym questionnaire consists of a total of 42 questions divided between five subscales (i.e., physical well-being, social/family well-being, emotional well-being, functional well-being and lymphoma subscale). Each subscale questionnaire rates each question on a 5-point scale from 0 = Not at all to 4 = Very much. These scores were summed to three total sum scores, namely FACT-Lym score, FACT-Lym Trial Outcome Index (TOI), FACT-General (FACT-G) and FACT-Lym total score. Total scores: FACT-Lym=0-60, FACT-TOI=0-116, FACT-G total=0-108, FACT-Lym Total= 0-168. Higher scores are reflective of better HRQoL.	Baseline and Week 48
Time to First Improvement in FACT-Lym, FACIT-Fatigue Score and ECOG Performance Status	Improvement was defined by the upper limit of the minimally important difference (MID). Patients with the best possible score at Baseline were excluded from this analysis because their HRQoL cannot be further improved. Responders and non-responders for each endpoint were defined based on change from baseline scores using pre specified cut-off points. Patients with an improved score compared to Baseline, for which the magnitude of the change was at least the cutoff value, were classified as responders; otherwise, as non-responders. The responder cutoff: ECOG cutoff=1, range=0 to 5, FACT-Lym cutoff=5.4, range 0-60, FACIT-Fatigue =5 and range=0-52.The median time to first improvement was estimated using the Kaplan Meier method and time to improvement event was determined based on upper bound of the MID. The time to improvement was calculated from the date of first study drug administration.	Baseline up to approximately 5 years
Medical Resource Utilization up to 5 Years	Percentage of patients requiring medical resources (blood transfusions, hospitalization, emergency room visits, general practitioners or specialists consultations, urgent care or splenic irradiation) up to 5 years.	Baseline up to approximately 5 years.

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19.
• Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, Garcia-Hernandez C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hanel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4.
• Tavares R, Souza CA, Paley C, Bouard C, Tiwari R, Pasquini R. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort. Hematol Transfus Cell Ther. 2020 Jan-Mar;42(1):46-53. doi: 10.1016/j.htct.2019.01.009. Epub 2019 Apr 25.
• Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016 Sep;101(9):1065-73. doi: 10.3324/haematol.2016.143677. Epub 2016 May 31.

Study record dates

Study Major Dates

• Study Start: August 16, 2011
• Primary Completion (Actual): January 26, 2017
• Study Completion (Actual): January 26, 2017

Study Registration Dates

• First Submitted: December 13, 2011
• First Submitted That Met QC Criteria: December 14, 2011
• First Posted (Estimate): December 16, 2011

Study Record Updates

• Last Update Posted (Actual): April 26, 2019
• Last Update Submitted That Met QC Criteria: April 25, 2019
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Keywords: Ruxolitinib; Myelofibrosis; INC424; PMF; PPV MF; PET-MF; Post-essential thrombocythemia myelofibrosis; Primary myelofibrosis; Post polycythemia myelofibrosis
• Additional Relevant MeSH Terms: Bone Marrow Diseases; Hematologic Diseases; Hemorrhagic Disorders; Myeloproliferative Disorders; Blood Coagulation Disorders; Blood Platelet Disorders; Primary Myelofibrosis; Thrombocytosis; Thrombocythemia, Essential; Polycythemia
• Other Study ID Numbers: CINC424A2401; 2010-024473-39 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No